505 related articles for article (PubMed ID: 26118797)
1. Performance and image enhancing drug injectors' access to needle syringe programs: Responding to a public policy dilemma.
van Beek I; Chronister KJ
Int J Drug Policy; 2015 Sep; 26(9):868-74. PubMed ID: 26118797
[TBL] [Abstract][Full Text] [Related]
2. Health risk and health seeking behaviours among people who inject performance and image enhancing drugs who access needle syringe programs in Australia.
Van de Ven K; Maher L; Wand H; Memedovic S; Jackson E; Iversen J
Drug Alcohol Rev; 2018 Nov; 37(7):837-846. PubMed ID: 29968372
[TBL] [Abstract][Full Text] [Related]
3. Risk and blood-borne virus testing among men who inject image and performance enhancing drugs, Sydney, Australia.
Rowe R; Berger I; Yaseen B; Copeland J
Drug Alcohol Rev; 2017 Sep; 36(5):658-666. PubMed ID: 28244160
[TBL] [Abstract][Full Text] [Related]
4. Maintaining the healthy body: Blood management and hepatitis C prevention among men who inject performance and image-enhancing drugs.
Fomiatti R; Lenton E; Latham JR; Fraser S; Moore D; Seear K; Aitken C
Int J Drug Policy; 2020 Jan; 75():102592. PubMed ID: 31855731
[TBL] [Abstract][Full Text] [Related]
5. Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs.
Larance B; Degenhardt L; Copeland J; Dillon P
Drug Alcohol Rev; 2008 Nov; 27(6):679-86. PubMed ID: 18825549
[TBL] [Abstract][Full Text] [Related]
6. Higher HCV antibody prevalence among Indigenous clients of needle and syringe programs.
Ward J; Topp L; Iversen J; Wand H; Akre S; Kaldor J; Maher L
Aust N Z J Public Health; 2011 Oct; 35(5):421-6. PubMed ID: 21973248
[TBL] [Abstract][Full Text] [Related]
7. Secondary distribution of injecting equipment obtained from needle and syringe programmes by people injecting image and performance enhancing drugs: England and Wales, 2012-15.
Glass R; Hope VD; Njoroge J; Edmundson C; Smith J; McVeigh J; Parry J; Desai M
Drug Alcohol Depend; 2019 Feb; 195():40-44. PubMed ID: 30580202
[TBL] [Abstract][Full Text] [Related]
8. Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 1992-2013.
Hope VD; Harris R; McVeigh J; Cullen KJ; Smith J; Parry JV; DeAngelis D; Ncube F
J Acquir Immune Defic Syndr; 2016 Mar; 71(3):331-7. PubMed ID: 26361173
[TBL] [Abstract][Full Text] [Related]
9. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
Bird SM; Goldberg DJ; Hutchinson SJ
J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
[TBL] [Abstract][Full Text] [Related]
10. HCV prevalence and risk behaviours among injectors of new psychoactive substances in a risk environment in Hungary-An expanding public health burden.
Tarján A; Dudás M; Wiessing L; Horváth G; Rusvai E; Tresó B; Csohán Á
Int J Drug Policy; 2017 Mar; 41():1-7. PubMed ID: 27984762
[TBL] [Abstract][Full Text] [Related]
11. Estimating the cost-effectiveness of needle-syringe programs in Australia.
Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
[TBL] [Abstract][Full Text] [Related]
12. Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996-2015.
Graham S; Maher L; Wand H; Doyle M; Iversen J
Int J Drug Policy; 2017 Sep; 47():69-76. PubMed ID: 28735774
[TBL] [Abstract][Full Text] [Related]
13. HIV and Hepatitis C Virus Infection and Risk Behaviors Among Heterosexual, Bisexual, and Lesbian Women Who Inject Drugs in Australia.
Iversen J; Dolan K; Ezard N; Maher L
LGBT Health; 2015 Jun; 2(2):127-34. PubMed ID: 26790118
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and correlates of recent injecting drug use among gay and bisexual men in Australia: Results from the FLUX study.
Bui H; Zablotska-Manos I; Hammoud M; Jin F; Lea T; Bourne A; Iversen J; Bath N; Grierson J; Degenhardt L; Prestage G; Maher L
Int J Drug Policy; 2018 May; 55():222-230. PubMed ID: 29429864
[TBL] [Abstract][Full Text] [Related]
15. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study.
Cunningham EB; Hajarizadeh B; Amin J; Bretana N; Dore GJ; Degenhardt L; Larney S; Luciani F; Lloyd AR; Grebely J;
Int J Drug Policy; 2018 Apr; 54():18-25. PubMed ID: 29367011
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.
Todd CS; Nasir A; Stanekzai MR; Fiekert K; Sipsma HL; Vlahov D; Strathdee SA
Harm Reduct J; 2015 Oct; 12():22. PubMed ID: 26472126
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs.
Hope VD; McVeigh J; Begley E; Glass R; Edmundson C; Heinsbroek E; Kean J; Campbell J; Whitfield M; Morgan G; Acreman D; Smith J
Drug Alcohol Rev; 2021 May; 40(4):586-596. PubMed ID: 33164293
[TBL] [Abstract][Full Text] [Related]
19. Trends in sources and sharing of needles among people who inject drugs, San Francisco, 2005-2012.
Kim NJ; Jin H; McFarland W; Raymond HF
Int J Drug Policy; 2015 Dec; 26(12):1238-43. PubMed ID: 26365768
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004.
Falster K; Kaldor JM; Maher L;
J Urban Health; 2009 Jan; 86(1):106-18. PubMed ID: 18979201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
